Protocol for monitoring of neutralizing antibodies to various receptor-binding domains using the tANCHOR system.

ingentiumby ingentium

In Antibodies Literature.

Publication date: Jul 02, 2025

Neutralizing antibody analysis against SARS-CoV-2 variants requires assays that rapidly adapt to protein mutations. Here, we present a protocol for monitoring neutralizing antibodies to various receptor-binding domains using the tANCHOR system. We describe steps for displaying variant receptor-binding domains on HeLa cells and producing tagged soluble angiotensin-converting enzyme 2 (ACE2). We then detail the procedures for establishing a cell-based ELISA to measure serum neutralization efficiency, using ACE2 competition as a readout. For complete details on the use and execution of this protocol, please refer to Ivanusic et al. .

Open Access PDF

Concepts Keywords
Antibodies Antibody
Competition Cell Membrane
Enzyme Cell-based Assays
Mutations High-Throughput Screening
Readout Immunology
Microbiology

Semantics

Type Source Name
disease IDO protein
disease IDO cell
drug DRUGBANK Cysteamine
disease MESH COVID 19 pandemic
disease IDO assay
drug DRUGBANK Ademetionine
disease IDO reagent
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Phosphate ion
drug DRUGBANK Streptomycin
drug DRUGBANK Puromycin
drug DRUGBANK Trypsin
drug DRUGBANK Edetic Acid
drug DRUGBANK Acetic acid
drug DRUGBANK Potassium Chloride
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Glycerin
drug DRUGBANK Coenzyme M
drug DRUGBANK Cefaclor
drug DRUGBANK Water
drug DRUGBANK Amino acids
drug DRUGBANK Glycine
pathway REACTOME Digestion
disease IDO process
drug DRUGBANK Albendazole
drug DRUGBANK Ampicillin
disease MESH shock
drug DRUGBANK Histidine
disease IDO production
disease MESH death
drug DRUGBANK Roxithromycin
drug DRUGBANK Nitrogen
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Medical air
disease IDO endotoxin
drug DRUGBANK (S)-Des-Me-Ampa

Original Article

(Visited 4 times, 1 visits today)